The offering dilutes existing shareholders by ~10-15% based on current market cap, but the clinical data and Sanofi milestone provide fundamental validation. Watch for FDA feedback on REC-4881 registrational path and REC-1245 expansion data in 2H 2026/2027.
Price Chart
Executive Summary
Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data updates for REC-4881 in FAP and REC-1245 in solid tumors, plus a $10 million milestone from Sanofi for optioning a development candidate. The capital raise extends cash runway into 2029 but dilutes existing shareholders, while the clinical data and partnership milestone provide validation of the platform.
Key Financial Metrics
Key Facts
- $200 million underwritten common stock offering with Janus Henderson, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and others
- REC-4881 Phase 1b/2 in FAP: 47% median total polyp burden reduction at 12 weeks; 55% median upper GI polyp burden reduction; 85% of patients maintained reductions below baseline after 12 weeks off treatment
- REC-1245 Phase 1: 2 confirmed partial responses in endometrial cancer, 1 unconfirmed in liver cancer; 91.7% disease control rate at doses ≥45 mg
- Sanofi optioned first development candidate from collaboration, triggering $10 million milestone payment; total milestone payments to date $144 million
- Cash position of ~$561 million as of September 30, 2026 (preliminary, unaudited); expected cash runway into 2029 including offering proceeds
- Registrational trial for REC-4881 targeted for 2H 2027 pending FDA discussions
Financial Impact
$200 million gross proceeds from offering; $10 million milestone from Sanofi; cash runway extended into 2029
Risk Factors
- Dilution from $200 million offering may pressure stock near-term
- REC-4881 registrational trial initiation depends on FDA discussions and could be delayed
- REC-1245 data is early with small sample size; durability and broader efficacy uncertain
- Sanofi milestone payments are contingent on development progress; no guarantee of future milestones
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381614 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 424B5 | $3.47 $3.58 | ▼ −3.32% | ▼ −3.23% | $4.05 (−16.88%) |
Oct 15, 2026 12d ago | 8-K | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.05 (−2.64%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.05 (−2.64%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $4.05 (+2.64%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.05 (−2.64%) |
Oct 15, 2026 12d ago | 424B5 | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $4.05 (+2.64%) |
Oct 6, 2026 21d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $4.05 (−12.53%) |
Oct 6, 2026 21d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $4.05 (−12.53%) |
Sep 21, 2026 5w ago | 8-K | $3.97 $3.70 | ▼ −6.80% | ▼ −5.78% | $4.05 (+2.02%) |
Sep 10, 2026 6w ago | Insider Cluster | $3.20 $3.83 | ▲ +19.69% | ▲ +20.03% | $4.05 (+26.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers